311 related articles for article (PubMed ID: 34272253)
1. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
[No Abstract] [Full Text] [Related]
3. SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity.
Mrak D; Tobudic S; Koblischke M; Graninger M; Radner H; Sieghart D; Hofer P; Perkmann T; Haslacher H; Thalhammer R; Winkler S; Blüml S; Stiasny K; Aberle JH; Smolen JS; Heinz LX; Aletaha D; Bonelli M
Ann Rheum Dis; 2021 Oct; 80(10):1345-1350. PubMed ID: 34285048
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
Spiera R; Jinich S; Jannat-Khah D
Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
[No Abstract] [Full Text] [Related]
5. Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
Prendecki M; Clarke C; Edwards H; McIntyre S; Mortimer P; Gleeson S; Martin P; Thomson T; Randell P; Shah A; Singanayagam A; Lightstone L; Cox A; Kelleher P; Willicombe M; McAdoo SP
Ann Rheum Dis; 2021 Oct; 80(10):1322-1329. PubMed ID: 34362747
[TBL] [Abstract][Full Text] [Related]
6. Assessment of humoral and cellular immunity induced by the BNT162b2 SARS-CoV-2 vaccine in healthcare workers, elderly people, and immunosuppressed patients with autoimmune disease.
Malipiero G; Moratto A; Infantino M; D'Agaro P; Piscianz E; Manfredi M; Grossi V; Benvenuti E; Bulgaresi M; Benucci M; Villalta D
Immunol Res; 2021 Dec; 69(6):576-583. PubMed ID: 34417958
[TBL] [Abstract][Full Text] [Related]
7. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
Albach FN; Burmester GR; Biesen R
Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
[No Abstract] [Full Text] [Related]
8. Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report.
Golding B; Lee Y; Golding H; Khurana S
Ann Rheum Dis; 2021 Oct; 80(10):1359-1361. PubMed ID: 34272252
[No Abstract] [Full Text] [Related]
9. Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies.
Amodio D; Ruggiero A; Sgrulletti M; Pighi C; Cotugno N; Medri C; Morrocchi E; Colagrossi L; Russo C; Zaffina S; Di Matteo G; Cifaldi C; Di Cesare S; Rivalta B; Pacillo L; Santilli V; Giancotta C; Manno EC; Ciofi Degli Atti M; Raponi M; Rossi P; Finocchi A; Cancrini C; Perno CF; Moschese V; Palma P
Front Immunol; 2021; 12():727850. PubMed ID: 34671350
[TBL] [Abstract][Full Text] [Related]
10. Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Marty PK; Van Keulen VP; Erskine CL; Shah M; Hummel A; Stachowitz M; Fatis S; Granger D; Block MS; Duarte-García A; Warrington KJ; Theel ES; Zhou X; Zeng H; Specks U; Escalante P; Peikert T
Front Immunol; 2022; 13():834981. PubMed ID: 35154159
[TBL] [Abstract][Full Text] [Related]
11. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
Ruddy JA; Connolly CM; Boyarsky BJ; Werbel WA; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
Ann Rheum Dis; 2021 Oct; 80(10):1351-1352. PubMed ID: 34031032
[No Abstract] [Full Text] [Related]
12. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
Front Immunol; 2021; 12():726960. PubMed ID: 34671348
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Furer V; Eviatar T; Zisman D; Peleg H; Paran D; Levartovsky D; Zisapel M; Elalouf O; Kaufman I; Meidan R; Broyde A; Polachek A; Wollman J; Litinsky I; Meridor K; Nochomovitz H; Silberman A; Rosenberg D; Feld J; Haddad A; Gazzit T; Elias M; Higazi N; Kharouf F; Shefer G; Sharon O; Pel S; Nevo S; Elkayam O
Ann Rheum Dis; 2021 Oct; 80(10):1330-1338. PubMed ID: 34127481
[TBL] [Abstract][Full Text] [Related]
14. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques.
O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH
Front Immunol; 2021; 12():800723. PubMed ID: 34992610
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.
Arroyo-Sánchez D; Cabrera-Marante O; Laguna-Goya R; Almendro-Vázquez P; Carretero O; Gil-Etayo FJ; Suàrez-Fernández P; Pérez-Romero P; Rodríguez de Frías E; Serrano A; Allende LM; Pleguezuelo D; Paz-Artal E
J Clin Immunol; 2022 Feb; 42(2):240-252. PubMed ID: 34787773
[TBL] [Abstract][Full Text] [Related]
16. Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Braun-Moscovici Y; Kaplan M; Braun M; Markovits D; Giryes S; Toledano K; Tavor Y; Dolnikov K; Balbir-Gurman A
Ann Rheum Dis; 2021 Oct; 80(10):1317-1321. PubMed ID: 34144967
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
Simon D; Tascilar K; Fagni F; Krönke G; Kleyer A; Meder C; Atreya R; Leppkes M; Kremer AE; Ramming A; Pachowsky ML; Schuch F; Ronneberger M; Kleinert S; Hueber AJ; Manger K; Manger B; Berking C; Sticherling M; Neurath MF; Schett G
Ann Rheum Dis; 2021 Oct; 80(10):1312-1316. PubMed ID: 33958324
[TBL] [Abstract][Full Text] [Related]
18. Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series.
Connolly CM; Teles M; Frey S; Boyarsky BJ; Alejo JL; Werbel WA; Albayda J; Christopher-Stine L; Garonzik-Wang J; Segev DL; Paik JJ
Ann Rheum Dis; 2022 Feb; 81(2):291-293. PubMed ID: 34493492
[No Abstract] [Full Text] [Related]
19. Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination.
Leacy EJ; Teh JW; O'Rourke AM; Brady G; Gargan S; Conlon N; Scott J; Dunne J; Phelan T; Griffin MD; Power J; Mooney A; Naughton A; Kiersey R; Gardiner M; O'Brien C; Mullan R; Flood R; Clarkson M; Townsend L; O'Shaughnessy M; Dyer AH; Moran B; Fletcher JM; Zgaga L; Little MA;
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791279
[TBL] [Abstract][Full Text] [Related]
20. Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Friedman MA; Curtis JR; Winthrop KL
Ann Rheum Dis; 2021 Oct; 80(10):1255-1265. PubMed ID: 34493491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
